SCHEMBL25482249

SCHEMBL25482249

Cc1cccc(C(C)c2ccccc2F)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.41
RECQL P46063 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
CCR1 P32246 1/20 0.36
CCR8 P51685 1/20 0.36
NOS3 P29474 1/20 0.34
NOS2 P35228 1/20 0.34
LTC4S Q16873 1/20 0.34
ACHE P22303 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
GFER P55789 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HRH1 P35367 1/20 0.33
CXCR4 P61073 1/20 0.33
TRPV3 Q8NET8 1/20 0.32
MAP4K4 O95819 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21910134 0.83 LMNA (0.40) HTTRECQLLMNAMAPTCCR1
SCHEMBL21911303 0.79 HTT (0.42) HTTRECQLLMNAMAPTCCR1
SCHEMBL4333513 0.78 HTT (0.50) HTTRECQLLMNACCR1CCR8
SCHEMBL23055145 0.77 TRPV3 (0.41) HTTRECQLCCR1CCR8NOS3
SCHEMBL15903486 0.74 ACHE (0.43) MAPTACHEMEN1ALDH1A1KMT2A
SCHEMBL102150 0.71 CCR1 (0.50) HTTRECQLLMNACCR1CCR8
SCHEMBL23287487 0.70 HTT (0.39) HTTRECQLCCR1CCR8NOS3
SCHEMBL20391832 0.70 RECQL (0.44) HTTRECQLLMNACCR1CCR8
SCHEMBL2019306 0.69 CCR1 (0.48) HTTRECQLLMNACCR1CCR8
SCHEMBL18930049 0.69 HTT (0.52) HTTRECQLLMNACCR1CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG HTT 4775/4885RECQL 807/4885LMNA 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.